Health Canada has agreed to review a New Drug Submission (NDS) for Tofersen, for the treatment of amyotrophic lateral sclerosis (ALS) in adults with a mutation in the superoxide dismutase 1 (SOD1) gene.

🙌 A regulatory decision on the New Drug Submission is expected in early 2025. If approved, this therapy will become the first treatment in Canada to target a genetic cause of ALS.

Read the Biogen Canada In. Press release here :

Share this article.